



May 9, 2014

## **TG Therapeutics, Inc. to Host Conference Call on First Quarter 2014 Financial Results and Business Update**

### **Investor Conference Call to be Held Tuesday, May 13, 2014 at 8:30am ET**

NEW YORK, May 9, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq: TGTX), an innovative, clinical-stage biopharmaceutical company, today announced that a conference call will be held on Tuesday, May 13, 2014 at 8:30 a.m. ET to discuss results for the first quarter of 2014 and provide a business outlook for the remainder of 2014. Michael Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.

In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics First Quarter 2014 Earnings Call. A live webcast of the call will be available at [www.tgtherapeutics.com](http://www.tgtherapeutics.com) on the Events page located under the Investors & Media tab. An audio recording of the conference call will be available for replay at [www.tgtherapeutics.com](http://www.tgtherapeutics.com), for a period of 30 days after the call.

TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.

### **ABOUT TG THERAPEUTICS, INC.**

TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K-delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B - lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. TG Therapeutics is headquartered in New York City.

TGTX - G


CONTACT: Jenna Bosco

Director - Investor Relations

TG Therapeutics, Inc.

Telephone: 212.554.4351

Email: [ir@tgtxinc.com](mailto:ir@tgtxinc.com)



Source: TG Therapeutics, Inc.

News Provided by Acquire Media